Search Results
Your search for 3 matches 15340 pages
Showing 14251 - 14300Study Identifies Gene Mutations Associated With Aggressive Multiple Myeloma
Using whole-exome sequencing on newly diagnosed patients with multiple myeloma, British researchers identified 15 genes that were significantly mutated in a subset of patients and mapped how these mutations related to long-term survival. They found 90% of patients with very aggressive disease who...
Study Reveals Effects of Chemoradiation in Brains of Glioblastoma Patients
A study from Massachusetts General Hospital (MGH) Cancer Center researchers—the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients—revealed not only specific structural changes within patients’ brains, but also...
Adding Oxaliplatin to Preoperative Chemoradiotherapy and Postoperative Chemotherapy Improves Disease-Free Survival in Locally Advanced Rectal Cancer
Final results of the German phase III CAO/ARO/AIO-04 trial reported in The Lancet Oncology by Rödel et al showed that adding oxaliplatin to fluorouracil (5-FU)–based neoadjuvant chemoradiation and postoperative chemotherapy improved disease-free survival in patients with locally advanced ...
Combining Interleukin-2 With Imiquimod and Topical Retinoid Therapy May Be Effective Against Cutaneous Metastatic Melanoma
A novel combination therapy appears to be effective in treating patients with melanoma skin metastases, according to new research from the University of California (UC) Davis. Led by Emanual Maverakis, MD, of the UC Davis Department of Dermatology, the research found that interleukin-2...
Researchers Identify Nerve-Guiding Protein That May Be Associated With Pancreatic Cancer Metastasis
Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease metastasizes in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer and were published by Foley et...
Reduced Short-Term Effects With Hypofractionated Whole-Breast Irradiation After Breast-Conserving Surgery
In a randomized trial reported in JAMA Oncology, Shaitelman et al found that hypofractionated whole-breast irradiation resulted in reduced short-term effects compared with conventional fractionation in women with stage 0 to II breast cancer undergoing breast-conserving surgery. Study Details In...
French Phase II Trial Suggests No Benefit of Adding Bevacizumab to Paclitaxel in Advanced Angiosarcoma
In a French phase II trial reported in the Journal of Clinical Oncology, Ray-Coquard et al found no apparent benefit of paclitaxel plus bevacizumab (Avastin) compared with weekly paclitaxel in patients with inoperable locally advanced or metastatic angiosarcoma. Study Details In this...
Medullablastomas Can Be Classified Noninvasively at Diagnosis
Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups, each with a different risk profile requiring subgroup-specific therapy. Currently, subgroup determination is done after surgical removal of the tumor. Investigators at...
Investigational Topical Gel Is Safe and Effective in Patients With Cutaneous T-Cell Lymphoma, Phase I Trial Shows
Results of a phase I trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early-stage cutaneous T-cell lymphoma. Currently, there is no cure for...
Key Genetic Factor in Cell Proliferation in Moles Identified
Scientists have known for years that a mutation in the BRAF gene makes moles start to grow but until now have not understood why they sometimes do not become cancerous. Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that...
Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer
In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...
ASCO Statement: Improving the Evidence Base for Treating Older Adults With Cancer
Older persons are the fastest growing segment of the U.S. population and account for the majority of cancer diagnoses and deaths and the majority of cancer survivors. However, since this population is underrepresented in clinical trials, the evidence base for treating older patients is poor. As...
17-Year Follow-up Indicates Early but Not Overall Reduction in Breast Cancer Mortality With Annual Mammography Screening at Age 40-49 Years
The 17-year follow-up in the UK Age trial, reported in The Lancet Oncology by Moss et al, indicated a reduction in breast cancer mortality during the first 10 years after diagnosis but not thereafter among women invited for annual mammography screening from age 40 to 49 years compared with...
Proteins Found in Urine May Serve as Biomarker for Early-Stage Pancreatic Cancer
A team of researchers at Barts Cancer Institute–Queen Mary University of London has discovered a combination of three proteins found at high levels in urine that can accurately detect early-stage pancreatic cancer. The discovery could lead to a noninvasive, inexpensive test to...
Biomarker Signature May Predict Aggressive Disease in African American Men With Prostate Cancer
In a study reported in Journal of Clinical Oncology, Yamoah et al identified a biomarker signature that may predict aggressive disease in African American men with prostate cancer. Study Details In the study, distribution of mRNA expression levels of 20 biomarkers associated with prostate cancer...
ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Van Poznak et al, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer. The statement is based on an ASCO expert panel assessment of systematic reviews, ...
No Difference in Overall Survival With Addition of Quinolone Derivative Vosaroxin to Cytarabine in Relapsed or Refractory AML
In a phase III VALOR trial reported in The Lancet Oncology, Ravandi et al found that the addition of the quinolone derivative vosaroxin to cytarabine did not significantly improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML). However, differences favoring...
Intraperitoneal Plus Intravenous Chemotherapy—an Underused Strategy—May Improve Survival in Advanced Ovarian Cancer
An observational study investigating the use and effectiveness of a combination regimen of intraperitoneal and intravenous chemotherapy in the treatment of advanced-stage ovarian cancer has found that although the dual approach substantially improved survival—81% of those treated with the...
Improved Outcomes With Aromatase Inhibitors vs Tamoxifen in Early Breast Cancer
In a patient-level meta-analysis of randomized trials reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 5 years of aromatase inhibitor treatment significantly reduced the recurrence risk vs 5 years of tamoxifen therapy during the first 4 years and...
Modified Mullerian-Inhibiting Substance Suppresses Growth of Some Recurrent Ovarian Tumors in Mouse Model
Use of gene therapy to deliver a protein that suppresses the development of female reproductive organs may improve the survival of patients with ovarian cancer that has recurred after chemotherapy. In a study published by Pepin et al in PNAS Early Edition, a Massachusetts General Hospital (MGH)...
Phase II Study Evaluates Neoadjuvant Eribulin vs Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Locally Advanced HER2-Negative Breast Cancer
In a randomized phase II trial (NSABP FB9) reported in Breast Cancer Research and Treatment, Abraham and colleagues found no improvement in pathologic complete response rate with neoadjuvant eribulin (Halavan) vs weekly paclitaxel followed by doxorubicin/cyclophosphamide in women with locally...
EORTC Trial Shows Marginal Overall Survival and Significant Disease-Free Survival Benefit of Adding Regional Nodal Irradiation in Early Breast Cancer
In a phase III trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Radiation Oncology and Breast Cancer Groups, the addition of regional nodal irradiation to whole-breast or thoracic-wall irradiation after surgery produced a marginal overall survival benefit...
ASCO Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
As reported by Schnipper et al in the Journal of Clinical Oncology, the ASCO Value in Cancer Care Task Force has released an ASCO statement detailing a conceptual framework to assess the value of cancer treatment options. The aim of ASCO in developing the framework is to encourage more...
Reduced Relapse but No Overall Survival Benefit With Adjuvant Lymph-Node Field Radiotherapy in High-Risk Melanoma
The 6-year follow-up of the phase III ANZMTG 01.02/TROG 02.01 trial, reported in The Lancet Oncology by Henderson et al, showed that adjuvant lymph-node field radiotherapy in melanoma patients with high risk of lymph-node field recurrence reduced the rate of recurrence but did not improve overall...
Study Finds Exercise in Adolescence Is Linked to Reduced Mortality From Cancer and All Causes in Later Life
A large, population-based prospective cohort study of about 75,000 women has found that adolescent exercise is associated with reduced risk of death due to cancer, cardiovascular disease, and all causes among middle-aged and older women. After adjusting for socioeconomic and lifestyle factors, the...
Omitting Doxorubicin From Postoperative Chemotherapy Has No Significant Survival Effect in Intermediate-Risk Wilms Tumor
In a phase III noninferiority trial (SIOP WT 2001) reported in The Lancet, Pritchard-Jones et al in the SIOP (International Society of Paediatric Oncology) Renal Tumours Study Group found that omission of doxorubicin from postoperative chemotherapy for stage II to III histologic intermediate-risk...
County-Based Analysis Suggests Widespread Overdiagnosis of Breast Cancer in Mammography Screening
In a study reported in JAMA Internal Medicine, Harding et al found that on the county level in the United States, mammography screening for breast cancer is associated with an increase in detection of small breast cancers but no reduction in breast cancer mortality. Study Details This ecologic...
Poor Survival in Patients With Multiple Myeloma Linked to Genetic Variation
As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that patients with multiple myeloma with a genetic variation in the gene FOPNL die, on average, 1 to 3 years sooner than patients without it. The finding was identified with...
FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...
No Survival Benefit of Adding MET Inhibitor Tivantinib to Erlotinib in Previously Treated Advanced Nonsquamous NSCLC
In a phase III trial reported in the Journal of Clinical Oncology, Scagliotti et al found that the addition of the MET receptor tyrosine kinase inhibitor tivantinib to erlotinib (Tarceva) did not improve overall survival in previously treated patients with locally advanced or metastatic nonsquamous ...
T-cell Receptor Therapy Achieves Encouraging Clinical Responses in Multiple Myeloma
Results from a clinical trial investigating a new T-cell receptor therapy demonstrated a clinical response in 80% of patients with multiple myeloma who had advanced disease after undergoing autologous stem cell transplants. Researchers at Penn’s Abramson Cancer Center modified T cells to ...
Study Shows Palliative Chemotherapy in Patients With End-Stage Cancer Did Not Improve Quality of Life and May Be Harmful
Although palliative chemotherapy is used to improve quality of life for patients with end-stage cancer, a study evaluating its use found that palliative chemotherapy did not improve quality of life near death for patients with a moderate or poor performance status and that it worsened quality of...
Low Incidence of Infusion-Related Reactions Reported With 30-Minute Ipilimumab Infusion
In a single-institution study reported in the Journal of Clinical Oncology, Momtaz et al found that the rate of infusion-related reactions remained acceptably low when ipilimumab (Yervoy) 3 mg/kg was infused over 30 minutes in patients with advanced melanoma. The currently approved dose of...
Adding Neoadjuvant mFOLFOX6 After Chemoradiation May Improve Pathologic Complete Response Rate in Locally Advanced Rectal Cancer
In a phase II trial reported in The Lancet Oncology, Garcia-Aguilar et al found that adding neoadjuvant mFOLFOX6 (modified fluorouracil [5-FU], leucovorin, oxaliplatin) after chemoradiation improved the pathologic complete response rate in patients with locally advanced rectal cancer undergoing...
German Study Shows Urea Cream Better Than Antioxidant Ointment in Preventing Capecitabine-Associated Hand-Foot Syndrome
In a phase III study reported in the Journal of Clinical Oncology, Hofheinz et al found that 10% urea cream was better at preventing capecitabine-related hand-foot syndrome than a new ointment (Mapisal) available in Germany that contains several antioxidants and exhibits high radical protection....
No Progression-Free Survival Benefit of Adding VEGF Inhibitor Cediranib to First-Line Chemotherapy in Advanced Biliary Tract Cancer
In a UK randomized phase II trial (ABC-03) reported in The Lancet Oncology, Valle et al found that adding the VEGF inhibitor cediranib to first-line cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer. Study Details In the double-blind...
‘Pill on a String’ Could Help Spot Early Signs of Esophageal Cancer
A “pill on a string” developed by researchers at the University of Cambridge could help doctors detect esophageal cancer at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published by Ross-Innes et al in Nature Genetics. The...
Cancer Diagnosis Among Patients With Diabetes Reduced Adherence to Evidence-Based Diabetes Medications
“A cancer diagnosis among patients with diabetes reduced adherence with evidence-based medications, particularly if patients’ life expectancy was short,” according to a study among Medicare beneficiaries reported in the Journal of Oncology Practice. “These findings emphasize ...
No Benefit of Adding Gefitinib to Platinum-Based Doublet in EGFR-Mutant NSCLC After Progression on First-Line Gefitinib
In a phase III IMPRESS trial reported in The Lancet Oncology, Soria et al found no progression-free survival benefit of adding gefitinib (Iressa) to platinum-based doublet chemotherapy in patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC) who had acquired resistance to...
Circulating DNA and Protein Biomarkers May Be Associated With Benefit of Regorafenib in Metastatic Colorectal Cancer
In a retrospective study reported in The Lancet Oncology, Tabernero et al used commercially available BEAMing technology to assess plasma tumor DNA and protein levels in a subgroup of patients from the CORRECT trial of regorafenib (Stivarga) in metastatic colorectal cancer and examined the...
Study Identifies Mechanism Fueling Growth of Pancreatic and Prostate Cancer Cells
UCLA Jonsson Cancer Center scientists have identified a new mechanism that delivers a key substance that fuels the growth of pancreatic and prostate cancer cells, a finding that offers new hope in the fight against two of the deadliest forms of the disease. Their findings were published by...
High-Dose Chemoradiotherapy and Watchful Waiting May Be Alternative to Surgery in Some Patients With Distal Rectal Cancer
In a Danish prospective observational study reported in The Lancet Oncology, Appelt et al found that high-dose chemoradiotherapy and watchful waiting may be an alternative to abdominoperineal resection in some patients with distal rectal cancer. Study Details In the study, 55 patients with...
Afatinib Improves Progression-Free Survival vs Erlotinib in Second-Line Treatment of Advanced Squamous Cell Carcinoma of the Lung
In the phase III LUX-Lung 8 trial reported in The Lancet Oncology, Soria et al found that the irreversible ErbB-family inhibitor afatinib (Gilotrif) significantly improved progression-free and overall survival vs the EGFR tyrosine kinase inhibitor erlotinib as second-line treatment in patients with ...
Belinostat Active in Relapsed/Refractory Peripheral T-Cell Lymphoma
In the phase II BELIEF trial reported in the Journal of Clinical Oncology, O’Connor et al found that the pan–histone deacetylase inhibitor belinostat (Beleodaq) produced durable responses in patients with relapsed/refractory peripheral T-cell lymphoma. The study supported the U.S. Food...
Stereotactic Body Radiotherapy Yields Similar Outcomes in Patients With Biopsy-Proven vs Radiographically Diagnosed Early-Stage NSCLC
In patients with early-stage non–small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy, outcomes were similar between patients with biopsy-proven lesions and those with radiographically diagnosed disease, according to a study by Fischer-Valuck et al in Tumori Journal....
Extended-Field Intensity-Modulated Radiation Therapy for Cervical and Endometrial Cancers Does Not Increase Risk of Duodenal Toxicity
Women with cervical or endometrial cancer who require treatment to the para-aortic lymph nodes can safely receive extended-field intensity-modulated radiation therapy without increased risk of duodenal toxicity, according to a study by Xu et al in Practical Radiation Oncology. Extended-Field...
Study Finds Breast Cancer Survivors Gain More Weight Than Cancer-Free Women
A prospective study examining weight gain in breast cancer survivors compared with cancer-free women from a familial risk cohort has found that, overall, breast cancer survivors gained significantly more weight than cancer-free women of the same age and menopausal status. According to the study...
FDA Approves Gefitinib for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved gefitinib (Iressa) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an...
Treatment With PI3K Inhibitors May Cause Cancers to Become More Aggressive and Metastatic
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only ...
Modeling Indicates Greater Benefit Without Greater Cost for Increased Colorectal Adenoma Detection Rate in Colonoscopy Screening
In a study reported in JAMA by Meester et al, microsimulation modeling of data from a U.S. community-based health-care system showed that colorectal cancer incidence and mortality were reduced with increased adenoma detection rate in colonoscopy screening, with no increase in total costs. Study...
